Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Valemetostat in Hepatic Impairment
NCT04276662Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of valemetostat in adult T-cell leukemia-lymphoma (ATLL) and peripheral T-cell lymphoma (PTCL) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum Concentration of DS-3201a, Area under the concentration-time curve from time zero to time of last measurable concentration and 5 more. Started Nov 2019; status: completed.
02
Drugs
valemetostat
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04276662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04276662.